Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888139 | 0.91 | SMN1; SMN2 (0.42) | CSNK2A1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL27639456 | 0.89 | MAPT (0.38) | CSNK2A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL161592 | 0.85 | CSNK2A1 (0.47) | CSNK2A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL596640 | 0.85 | L3MBTL1 (0.37) | RAB9AMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL4887608 | 0.84 | L3MBTL1 (0.45) | CSNK2A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL4881875 | 0.84 | L3MBTL1 (0.40) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL687572 | 0.82 | MAPT (0.39) | CSNK2A1MAPTKMT2AMEN1USP2 | |
| SCHEMBL16973600 | 0.82 | L3MBTL1 (0.38) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL1691562 | 0.82 | MCHR1 (0.40) | NPC1RAB9AMAPTKMT2AMEN1 | |
| SCHEMBL28609134 | 0.81 | HTR2C (0.38) | NPC1RAB9AALDH1A1PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-104411312-B | The combination for being used in treatment neurological or dysbolism use including PDE2 the inhibitor such as methyl of 1 aryl 4 [1,2,4] triazole [4,3 A] quinoxaline compounds and PDE10 inhibitor | 詹森药业有限公司 | 2018-03-06 | — | — | CN | disclosed |
| CN-107690281-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2018-02-13 | — | — | CN | disclosed |
| CN-104411312-A | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders | JANSSEN PHARMACEUTICA NV | 2015-03-11 | — | — | CN | disclosed |
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | CULSHAW ANDREW JAMES | 2008-11-27 | — | — | US | disclosed |
| CN-100432059-C | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | CULSHAW ANDREW J | 2006-07-13 | — | — | US | disclosed |
| CN-1711249-A | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2005-12-21 | — | — | CN | disclosed |
| CN-1138762-C | Phenylpyridazinones | — | 2004-02-18 | — | — | CN | disclosed |
| US-20030119673-A1 | Phenylpyridazinones | LINKER KARL-HEINZ (DE) | 2003-06-26 | — | — | US | disclosed |
| CN-1192208-A | Phenylpyridazinones | BAYER AG (DE) | 1998-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | OPRK1, OPRL1, TRPV1 | CSNK2A1 413/4885NPC1 3242/4885RAB9A 1166/4885 |
| US-20030119673-A1 | Phenylpyridazinones | CYP2D6, CYP1A1, CYP1B1 | CSNK2A1 2296/4885NPC1 4089/4885RAB9A 2247/4885 |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP1, FABP4 | CSNK2A1 4398/4885NPC1 268/4885RAB9A 3995/4885 |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | OPRK1, OPRL1, TRPV1 | CSNK2A1 413/4885NPC1 3242/4885RAB9A 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.